Skip to main content
Top
Published in: International Urology and Nephrology 2/2019

01-02-2019 | Nephrology - Original Paper

Evaluating the associations between urinary excretion of magnesium and that of other components in calcium stone-forming patients

Authors: Sanaz Tavasoli, Maryam Taheri, Fatemeh Taheri, Abbas Basiri, Fahimeh Bagheri Amiri

Published in: International Urology and Nephrology | Issue 2/2019

Login to get access

Abstract

Purpose

Magnesium plays numerous vital roles in human’s body. It is known as a protective factor in stone formation by binding to oxalate in the intestinal and urinary system, and decreasing its absorption and crystallization, respectively. Due to controversies about the association between the 24-h urine magnesium and other urine metabolites in different studies, this study was designed to find a clear answer to this question.

Methods

In this retrospective cross-sectional study, data from 24-h urinalysis of the calcium stone-forming (CSF) patients were assessed. The correlation between 24-h urine (24-U) magnesium to creatinine ratio (Mg/Cr) with other 24-U metabolites to creatinine ratio was assessed, using Spearman correlation test. The association between 24-U magnesium and 24-U oxalate was also studied in a multivariate logistic regression model.

Results

Among 965 patients, the level of Mg/Cr showed a direct association with all other 24-U metabolite to Cr ratio (p-value < 0.001 for all analyses). The result of multivariate regression analysis showed that the higher quartile of 24-U oxalate (> 47 mg/24 h) increased the odds of 24-U magnesium more than 75 mg/24 h (data median) (OR 1.89, 95% CI 1.14–3.13) comparing with the lower quartile of 24-U oxalate (≤ 26 mg/24 h).

Conclusions

In a routine dietary habit, since rich sources of magnesium contain a high amount of oxalate at the same time, it is not surprising that magnesium level in 24-h urinalysis showed a direct association with 24-h urine oxalate.
Literature
2.
go back to reference Cowan J (2002) Structural and catalytic chemistry of magnesium-dependent enzymes. Biometals 15:225–235CrossRefPubMed Cowan J (2002) Structural and catalytic chemistry of magnesium-dependent enzymes. Biometals 15:225–235CrossRefPubMed
3.
go back to reference Shils ME, Shike M (2006) Modern nutrition in health and disease. Lippincott Williams & Wilkins, Baltimore Shils ME, Shike M (2006) Modern nutrition in health and disease. Lippincott Williams & Wilkins, Baltimore
4.
go back to reference Levy FL, Adams-Huet B, Pak CY (1995) Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 98:50–59CrossRefPubMed Levy FL, Adams-Huet B, Pak CY (1995) Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 98:50–59CrossRefPubMed
6.
go back to reference Massey L (2005) Magnesium therapy for nephrolithiasis. Magnes Res 18:123–126PubMed Massey L (2005) Magnesium therapy for nephrolithiasis. Magnes Res 18:123–126PubMed
7.
go back to reference Preminger G, Baker S, Peterson R, Poindexter J, Pak C (1989) Hypomagnesiuric hypocitraturia: an apparent new entity for calcium nephrolithiasis. J Lithotr Stone Dis 1:22–25 Preminger G, Baker S, Peterson R, Poindexter J, Pak C (1989) Hypomagnesiuric hypocitraturia: an apparent new entity for calcium nephrolithiasis. J Lithotr Stone Dis 1:22–25
9.
go back to reference Nakada SY, Hoff DG, Attai S, Heisey D, Blankenbaker D, Pozniak M (2000) Determination of stone composition by noncontrast spiral computed tomography in the clinical setting. Urology 55:816–819CrossRefPubMed Nakada SY, Hoff DG, Attai S, Heisey D, Blankenbaker D, Pozniak M (2000) Determination of stone composition by noncontrast spiral computed tomography in the clinical setting. Urology 55:816–819CrossRefPubMed
11.
go back to reference Tiselius HG (1991) Aspects on estimation of the risk of calcium oxalate crystallization in urine. Urol Int 47:255–259CrossRefPubMed Tiselius HG (1991) Aspects on estimation of the risk of calcium oxalate crystallization in urine. Urol Int 47:255–259CrossRefPubMed
12.
13.
go back to reference Marangella M, Petrarulo M, Daniele PG, Sammartano S (2002) LithoRisk: a software for calculating and visualising nephrolithiasis risk profiles. G Ital Nefrol 19:693–698PubMed Marangella M, Petrarulo M, Daniele PG, Sammartano S (2002) LithoRisk: a software for calculating and visualising nephrolithiasis risk profiles. G Ital Nefrol 19:693–698PubMed
14.
go back to reference Bultitude MF (2012) Campbell-Walsh urology tenth edition. Elsevier, PhiladelphiaCrossRef Bultitude MF (2012) Campbell-Walsh urology tenth edition. Elsevier, PhiladelphiaCrossRef
16.
go back to reference Favus MJ, Goltzman G (2008) Regulation of calcium and magnesium. In: Rosen CJ, Bouillon R, Compston JE, Rosen V (eds) Primer on the metabolic bone diseases and disorders of mineral metabolism. Wiley, New York, pp 104–108 Favus MJ, Goltzman G (2008) Regulation of calcium and magnesium. In: Rosen CJ, Bouillon R, Compston JE, Rosen V (eds) Primer on the metabolic bone diseases and disorders of mineral metabolism. Wiley, New York, pp 104–108
Metadata
Title
Evaluating the associations between urinary excretion of magnesium and that of other components in calcium stone-forming patients
Authors
Sanaz Tavasoli
Maryam Taheri
Fatemeh Taheri
Abbas Basiri
Fahimeh Bagheri Amiri
Publication date
01-02-2019
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-2036-1

Other articles of this Issue 2/2019

International Urology and Nephrology 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.